Business
AxisBiotix-PsT approved for launch in Europe
AxisBiotix-PsT approved for launch in Europe.
About this update from Skinbiotherapeutics Plc
[{"type":"text","content":"\n \n \n \n \n SkinBioTherapeutics plc\n \n \n \n \n (\"SkinBioTherapeutics\" or \"the Company\")\n \n \n \n AxisBiotix-Ps™ receives health authority approval for European market launch\n \n \n \n \n \n \n \n \n ·\n \n First European launch for Axis-BioTix-Ps™ is in Spain from 13 March\n \n \n \n ·\n \n Next targets include Italy and then France\n \n \n \n ·\n \n Broader launch presents\n \n \n further validation of the benefits of this product and opens new geographical revenue streams\n \n \n \n \n 7 March 2023 -\n \n SkinBioTherapeutics plc (AIM: SBTX), a life science business focused on skin health, has announced the launch of AxisBiotix-Ps™, a food supplement to alleviate the symptoms associated with Psoriasis, into the Spanish market.\n \n \n Health authority authorisation in Spain was received on 3 March 2023 paving the way for the AxisBiotix-Ps™ supplement to be made available from 13 March 2023. Building on the initial launch in the UK where customer retention rates have risen to 80%+1, the launch of AxisBiotix-Ps into new markets in Europe is the next milestone in its commercialisation strategy.\n \n \n Sales in this new market will be managed directly by the AxisBiotix team in the UK, with products being distributed through the Company's EU hub in the Netherlands. Products will be sold through a country-specific website, with names and requisite labelling appropriate for the Spanish market and allowing opportunities for an expanded product range in future.\n \n \n The Spanish market presents an exciting opportunity for AxisBiotix-Ps\n ™\n where approximately 60% of people have sensitive skin and, like the UK, between 1-3% of these sufferers have psoriasis. The Company believes primary users will be those seeking natural methods to manage sensitive skin conditions associated with psoriatic skin. Data about Spain's population also shows that people are receptive to food supplements to improve health and wellness, with approximately 7 in 10 currently using them. \n \n \n The next target countries for launch are Italy and then France. Talks with the individual country regulators are currently underway and we expect commercialisation will commence during the year.\n \n \n \n Stuart J. Ashman, CEO of SkinBioTherapeutics, said:\n \n \n \"Our aim with AxisBiotix-Ps™ is to offer people a natural w...